We are live on ! Find out more
PCP

Pacific Capital Partners Portfolio holdings

AUM $116M
1-Year Est. Return 24.59%
This Fund
S&P 500
This Quarter Est. Return
+9.65%
1 Year Est. Return
+24.59%
3 Year Est. Return
+49.79%
5 Year Est. Return
10 Year Est. Return
AUM
$133M
AUM Growth
-$32.8M
Cap. Flow
-$125M
Cap. Flow %
-94.51%
Top 10 Hldgs %
48.36%
Holding
59
New
Increased
26
Reduced
28
Closed
3

Top Buys

Rank Stock Value
1
CBZ icon
CBIZ
CBZ
+$1.69M
2
CLH icon
Clean Harbors
CLH
+$410K
3
STRA icon
Strategic Education
STRA
+$263K
4
EXAS
Exact Sciences
EXAS
+$245K
5
CG icon
Carlyle Group
CG
+$145K

Top Sells

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$84.1M
2
NEE icon
NextEra Energy
NEE
+$4.7M
3
ICE icon
Intercontinental Exchange
ICE
+$3.97M
4
MOH icon
Molina Healthcare
MOH
+$3.53M
5
ICUI icon
ICU Medical
ICUI
+$3.18M

Sector Composition

Rank Sector Weight
1 Healthcare 47.6%
2 Industrials 23.25%
3 Financials 12.23%
4 Materials 6.25%
5 Consumer Discretionary 5.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CVSA
26
Covista Inc
CVSA
$4.51B
$1.55M 1.17%
26,227
-1,856
-7% -$99K
AXNX
27
DELISTED
Axonics, Inc. Common Stock
AXNX
$1.52M 1.14%
24,380
+1,000
+4% +$55.9K
BC icon
28
Brunswick
BC
$5.16B
$1.48M 1.12%
15,343
-1,913
-11% -$152K
CG icon
29
Carlyle Group
CG
$17.2B
$1.42M 1.07%
34,800
+4,396
+14% +$145K
TECK icon
30
Teck Resources
TECK
$31.9B
$1.37M 1.04%
32,500
-30,000
-48% -$1.15M
HOLX
31
DELISTED
Hologic
HOLX
$1.37M 1.03%
19,121
+346
+2% +$24.1K
HUM icon
32
Humana
HUM
$46.2B
$1.29M 0.97%
2,810
-633
-18% -$312K
ABBV icon
33
AbbVie
ABBV
$469B
$1.29M 0.97%
8,299
+150
+2% +$21.9K
TMO icon
34
Thermo Fisher Scientific
TMO
$229B
$1.08M 0.81%
2,035
+36
+2% +$17.4K
BSX icon
35
Boston Scientific
BSX
$73.5B
$1.05M 0.8%
18,244
+331
+2% +$17.7K
COO icon
36
Cooper Companies
COO
$14.9B
$1.05M 0.79%
11,056
+200
+2% +$16.8K
TMDX icon
37
Transmedics
TMDX
$3.22B
$991K 0.75%
12,553
+1,656
+15% +$99.9K
MRK icon
38
Merck
MRK
$369B
$985K 0.74%
9,031
+778
+9% +$80.8K
EXAS
39
DELISTED
Exact Sciences
EXAS
$960K 0.72%
12,981
+3,744
+41% +$245K
LULU icon
40
lululemon athletica
LULU
$13B
$872K 0.66%
1,705
-499
-23% -$216K
STRA icon
41
Strategic Education
STRA
$1.84B
$852K 0.64%
9,223
+3,034
+49% +$263K
COLM icon
42
Columbia Sportswear
COLM
$3.06B
$837K 0.63%
10,523
+190
+2% +$14.5K
AMP icon
43
Ameriprise Financial
AMP
$49.4B
$759K 0.57%
1,998
+36
+2% +$12.3K
PRCT icon
44
Procept Biorobotics
PRCT
$1.25B
$754K 0.57%
17,999
+3,653
+25% +$124K
CVS icon
45
CVS Health
CVS
$120B
$748K 0.56%
9,471
+171
+2% +$12.2K
NKE icon
46
Nike
NKE
$59.3B
$740K 0.56%
6,817
+951
+16% +$102K
FTV icon
47
Fortive
FTV
$17.8B
$736K 0.56%
13,270
-13,270
-50% -$700K
LLY icon
48
Eli Lilly
LLY
$1.12T
$726K 0.55%
1,246
+22
+2% +$12.8K
ECL icon
49
Ecolab
ECL
$79.6B
$697K 0.53%
3,515
+63
+2% +$11.3K
HCA icon
50
HCA Healthcare
HCA
$88.1B
$675K 0.51%
2,495
+45
+2% +$11.1K

Similar funds

Pacific Capital Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Pacific Capital Partners held 59 positions worth $133M, down 20% from $165M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Pacific Capital Partners withdrew a net $125M in Q4 2023, closing 3 positions and reducing 28 holdings. Its most notable exit was Alcon, an estimated $3.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 47% a quarter earlier, followed by Industrials and Financials.

Against the trend, Pacific Capital Partners added an estimated $1.69M to CBIZ.

  • Pacific Capital Partners added most to CBIZ in Q4 2023, an estimated $1.69M increase.
  • Pacific Capital Partners's biggest Q4 2023 reduction was Icon, cutting an estimated $84.1M.
  • Pacific Capital Partners fully exited Alcon in Q4 2023, selling an estimated $3.08M.
  • Pacific Capital Partners's ten largest holdings make up 48% of its $133M portfolio in Q4 2023.
  • Pacific Capital Partners opened 0 new positions and closed 3 in Q4 2023.
  • Pacific Capital Partners's portfolio value fell 20% quarter-over-quarter to $133M.

Based on Pacific Capital Partners's 13F filing for Q4 2023, filed 8 May 2025.